Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 95, Issue 6, Pages 691-709
Publisher
Wiley
Online
2020-04-02
DOI
10.1002/ajh.25792
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd
- (2020) Jerald P. Radich et al. BLOOD
- Dose Optimization in Elderly CML Patients Treated with Bosutinib after Intolerance or Failure of First-Line Tyrosine Kinase Inhibitors
- (2020) Fausto Castagnetti et al. BLOOD
- Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response
- (2020) Andreas Hochhaus et al. BLOOD
- An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia
- (2020) Qian Jiang et al. BLOOD
- FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial
- (2020) Mhairi Copland et al. BLOOD
- Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update
- (2020) Delphine Rea et al. BLOOD
- A Report on 114 Patients Who Experienced Treatment Free Remission in a Single Institution during a 15 Years Period: Long Term Follow-up, Late Molecular Relapses and Second Attempts
- (2020) Philippe Rousselot et al. BLOOD
- Long‐term results of frontline dasatinib in chronic myeloid leukemia
- (2020) Abhishek Maiti et al. CANCER
- Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemia
- (2020) Lucia Masarova et al. CANCER
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
- (2020) A. Hochhaus et al. LEUKEMIA
- Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
- (2019) Kamal Chamoun et al. Journal of Hematology & Oncology
- Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia
- (2019) Kiran Naqvi et al. CANCER
- Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
- (2019) Iman Abou Dalle et al. Cancer Medicine
- Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study
- (2019) Ya-Chen Tina Shih et al. Lancet Haematology
- Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis
- (2019) Timothy P. Hughes et al. BLOOD
- Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy
- (2019) Jorge E. Cortes et al. BLOOD
- Sudden blastic transformation in treatment‐free remission chronic myeloid leukaemia
- (2019) Mansour Alfayez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
- (2019) Timothy P. Hughes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
- (2018) Jorge E. Cortes et al. BLOOD
- Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia
- (2018) Kiran Naqvi et al. CANCER
- Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
- (2018) David M. Ross et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
- (2018) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
- (2018) Susanne Saussele et al. LANCET ONCOLOGY
- Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
- (2017) T P Hughes et al. LEUKEMIA
- Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
- (2017) A Hochhaus et al. LEUKEMIA
- The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
- (2017) Andrew A. Wylie et al. NATURE
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- (2017) Andreas Hochhaus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034
- (2016) Neil P. Shah et al. AMERICAN JOURNAL OF HEMATOLOGY
- Monitoring and defining early response: Where to draw the line?
- (2016) Susan Branford BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
- (2016) W. Wang et al. BLOOD
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- (2016) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients
- (2016) H Hjorth-Hansen et al. LEUKEMIA
- Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
- (2016) Bing Z. Carter et al. Science Translational Medicine
- Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial
- (2016) Jorge E Cortes et al. Lancet Haematology
- Chronic myeloid leukemia: First-line drug of choice
- (2015) Elias Jabbour AMERICAN JOURNAL OF HEMATOLOGY
- Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina
- (2015) Jianxiang Wang et al. BLOOD
- Why Are Cancer Drugs So Expensive in the United States, and What Are the Solutions?
- (2015) Hagop Kantarjian et al. MAYO CLINIC PROCEEDINGS
- Cost Structure and Clinical Outcome of a Stem Cell Transplantation Program in a Developing Country: The Experience in Northeast Mexico
- (2015) J. C. Jaime-Perez et al. ONCOLOGIST
- Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials
- (2015) Preetesh Jain et al. Lancet Haematology
- Having “Skin in the Game” and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs
- (2015) Hagop Kantarjian et al. JAMA Oncology
- The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors
- (2015) Tun Kiat Ko et al. Oncotarget
- JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo
- (2014) P. Gallipoli et al. BLOOD
- Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
- (2013) P. Jain et al. BLOOD
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies
- (2013) P. Neelakantan et al. BLOOD
- Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
- (2013) H. M. Kantarjian et al. BLOOD
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
- (2013) D. M. Ross et al. BLOOD
- HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia
- (2013) Paolo Strati et al. CANCER
- The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure
- (2013) Elias Jabbour et al. Clinical Lymphoma Myeloma & Leukemia
- Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase
- (2013) Maro Ohanian et al. Clinical Lymphoma Myeloma & Leukemia
- Advances in Immunotherapy of Chronic Myeloid Leukemia CML
- (2013) Stefanie Erika Held et al. CURRENT CANCER DRUG TARGETS
- Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months
- (2013) A. Nazha et al. HAEMATOLOGICA
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia
- (2012) J. P. Radich et al. BLOOD
- Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
- (2012) Xuelin Huang et al. CANCER
- Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
- (2012) David Montani et al. CIRCULATION
- Combination of pegylated IFN- 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
- (2011) B. Simonsson et al. BLOOD
- Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
- (2011) J. E. Cortes et al. BLOOD
- Considerations in the Management of Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy
- (2011) Hagop Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?
- (2011) Elias Jabbour et al. JOURNAL OF CLINICAL ONCOLOGY
- Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
- (2011) Rüdiger Hehlmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
- (2011) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results
- (2011) P D le Coutre et al. LEUKEMIA
- Sustained exposure to the DNA demethylating agent, 2′-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy
- (2010) Michael Schnekenburger et al. BIOCHEMICAL PHARMACOLOGY
- Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations
- (2010) E. Jabbour et al. BLOOD
- Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
- (2010) Elias Jabbour et al. CANCER
- Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance
- (2010) Tianjun Zhou et al. Chemical Biology & Drug Design
- Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
- (2010) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
- (2010) Claude Preudhomme et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
- (2009) M. C. Muller et al. BLOOD
- Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP
- (2009) N. Testoni et al. BLOOD
- Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia
- (2009) A. Quintas-Cardama et al. BLOOD
- Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
- (2009) L. Noens et al. BLOOD
- Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy
- (2009) Alfonso Quintás-Cardama et al. CANCER
- Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia
- (2009) Alfonso Quintás-Cardama et al. CANCER
- Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily
- (2009) Hagop Kantarjian et al. CANCER
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response
- (2009) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial
- (2009) Jane F. Apperley et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of BaselineBCR-ABLMutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
- (2009) Timothy Hughes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
- (2009) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
- (2008) S. J. Lee et al. BLOOD
- Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
- (2008) E. Jabbour et al. BLOOD
- Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?
- (2008) G J Ruiz-Argüelles et al. BONE MARROW TRANSPLANTATION
- Molecular monitoring in chronic myeloid leukemia
- (2008) Elias Jabbour et al. CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started